Global X China Biotech Innovation ETF
CHB was delisted on the 16th of February, 2024.
3 hedge funds and large institutions have $278K invested in Global X China Biotech Innovation ETF in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
50% more funds holding
Funds holding: 2 → 3 (+1)
44% more capital invested
Capital invested by funds: $193K → $278K (+$85K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$84.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$9.44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$5.35K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $183K | -$5.35K | -713 | -3% |
|
|
2
Jane Street
New York
| $84.9K | +$84.3K | +11,229 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $9.51K | +$9.44K | +1,258 | New |
|
|
4
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | -100 | Closed |
|
CHB Hedge Fund Activity: Q3 2023 in Review
3 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Global X China Biotech Innovation ETF (CHB) for Q3 2023, worth a combined $278K — up 44% from $193K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CHB positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $84.3K. The largest seller was Citadel Advisors, cutting an estimated $5.35K.
- 3 institutional investors held Global X China Biotech Innovation ETF (CHB) as of Q3 2023, up from 2 in Q2 2023.
- Funds reported $278K of Global X China Biotech Innovation ETF stock for Q3 2023, up 44% quarter-over-quarter.
- 2 funds opened new Global X China Biotech Innovation ETF positions in Q3 2023 and 1 closed out, a net change of +1 holder.
- The largest Global X China Biotech Innovation ETF buyer in Q3 2023 was Jane Street, an estimated $84.3K added.
- The largest Global X China Biotech Innovation ETF seller in Q3 2023 was Citadel Advisors, an estimated $5.35K sold.
Based on aggregated 13F filings for Q3 2023.